Role of oral probiotics to ameliorate gut microbiota dysbiosis in psoriasis therapy: A literature review
Keywords:
Psoriasis, Microbiome, Dybiosis, Probiotic, Human and healthAbstract
Psoriasis is a chronic and recurring inflammatory condition that can occur locally in the skin and systemically. Psoriasis cause significant morbidity and reduce the patient’s quality of life. Microbiota and its metabolites are known to play a significant role in both innate and adaptive immune regulation. Disruption of microbial homeostasis known as dysbiosis, can lead to alterations in immunological regulation and disruption of the gastrointestinal barrier. The gut microbiota composes the largest microbiome in the human body. Changes in the diversity of the gut microbiotas and their metabolites are reported in psoriasis patients. Dysbiosis is thought to contribute and intensify the inflammatory process in psoriasis. Probiotics are widely utilized and well-known for its safety profile. Probiotics are currently being widely studied as a therapy for skin disorders, including psoriasis. Probiotics may increase the variety of commensal microbiota, decrease pathobionts, and restore the damaged of the gastrointestinal epithelium. Probiotic supplementation is expected to ameliorate the dysbiosis that occurs in psoriasis and become a promising adjuvant therapy in psoriasis.References
Gudjonsson JE, Elder JT. Psoriasis. In: Kang S et al, editor. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw-Hill; 2019. p. 458–532.
Myers B, Brownstone N, Reddy V, Chan S, Thibodeaux Q, Truong A, et al. The gut microbiome in psoriasis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2019;33(6):101494.
Atabati H, Esmaeili SA, Saburi E, Akhlaghi M, Raoofi A, Rezaei N, et al. Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies. J Cell Physiol. 2020;235(12):8925–37.
Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. British Journal of Dermatology. 2021;184(1):14–24.
Freedman NJ. From Colon to Aortic Aneurysm: Trek of the Treg. Vol. 7, JACC: Basic to Translational Science. Elsevier Inc.; 2022. p. 948–50.
Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol [. 2017;17(4):219–32. Available from: http://dx.doi.org/10.1038/nri.2017.7
Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A. Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis. Int J Mol Sci. 2021;22(8).
Navarro‐lópez V, Núñez‐delegido E, Ruzafa‐costas B, Sánchez‐pellicer P, Agüera‐santos J, Navarro‐moratalla L. Probiotics in the therapeutic arsenal of dermatologists. Microorganisms. 2021;9(7).
Rather IA, Bajpai VK, Huh YS, Han YK, Bhat EA, Lim J, et al. Probiotic Lactobacillus sakei proBio-65 extract ameliorates the severity of imiquimod induced psoriasis-like skin inflammation in a mouse model. Front Microbiol. 2018;9(MAY):1–11.
Chen YH, Wu CS, Chao YH, Lin CC, Tsai HY, Li YR, et al. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J Food Drug Anal. 2017;25(3):559–66.
Groeger D, Mahony LO, Murphy EF, Bourke JF, Timothy G, Kiely B, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–39.
Vijayashankar M, Raghunath N. Pustular psoriasis responding to Probiotics – a new insight. Our Dermatology Online. 2012;3(4):326–9.
Navarro-López V, Martínez-Andrés A, Ramírez-Boscá A, Ruzafa-Costas B, Núñez-Delegido E, Carrión-Gutiérrez MA et al. Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial. Acta Derm Venereol. 2019;(99):1078–84.
Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017;8(2):143–51.
Nole KLB, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol. 2014;71(4):814–21.
